The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

• Κύριοι συγγραφείς: Chih-Jen Yang (Συγγραφέας), Ming-Ju Tsai (Συγγραφέας), Jen-Yu Hung (Συγγραφέας), Mei-Hsuan Lee (Συγγραφέας), Ying-Ming Tsai (Συγγραφέας), Yu-Chen Tsai (Συγγραφέας), Jui-Feng Hsu (Συγγραφέας), Ta-Chih Liu (Συγγραφέας), Ming-Shyan Huang (Συγγραφέας), Inn-Wen Chong (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: BMC, 2017-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg dai...